SAN ANTONIO--(BUSINESS WIRE)--Azaya Therapeutics Inc., a clinical-stage oncology company developing more effective cancer treatments through its nanotechnology platform, announced an exclusive license ...
Cytori Therapeutics said today it plans to acquire the liposomal nanoparticle technology platform of Azaya Therapeutics for up to $170 million, in a deal designed to expand and complement the buyer’s ...
Parexo Labs, a division of Azaya, launches as a new CDMO with an emphasis on nanotechnology and liposomal manufacturing. Azaya Therapeutics, a biopharmaceutical company focused on focused on ...
Cytori Therapeutics Inc. stock surged 7.9% to $1.78 per share in morning trade Thursday after the company said it had agreed to purchase assets from privately-held Azaya Therapeutics. Under the terms ...
Cytori Therapeutics is set to gain cancer drugs and a liposomal nanoparticle technology platform through the acquisition of Azaya Therapeutics. The lead drug is a formulation of doxorubicin, the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Azaya Therapeutics is conducting a study of a generic ...
> We all know that one of the most valuable resources in the clinical research industry is experienced staff. Yet it is commonly accepted that a clinical monitor will only stay with a company for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results